<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04251364</url>
  </required_header>
  <id_info>
    <org_study_id>Expedition5300</org_study_id>
    <nct_id>NCT04251364</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Mountain Sickness</brief_title>
  <acronym>Exp5300</acronym>
  <official_title>Acetazolamide and Statins for the Treatment of Chronic Mountain Sickness in Highlanders: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d’Expertise sur l’Altitude EXALT</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre d’Expertise sur l’Altitude EXALT</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the effect of two drugs for the treatment of chronic mountain
      sickness in highlanders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 100 million individuals reside at high altitude (&gt;2500m) worldwide, with the largest
      populations of highlanders being found in South America (Andean), central Asia (Tibetan and
      Sherpa) and East Africa (Ethiopian). Despite unique adaptations to hypoxia in these
      populations, chronic mountain sickness (CMS) is a clinical syndrome which is observed in
      5-33% of individuals residing permanently at high altitude.Several pharmacological approaches
      have been proposed in the treatment of EE and CMS. However, few studies show sufficient
      clinical evidence for safety and efficacy in CMS treatment and most highlanders with CMS
      remain untreated. The present project aims to better characterize chronic hypoxic responses
      in highlanders and to evaluate the interest of acetazolamide and statins as potential
      treatments for chronic mountain sickness.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hematocrit</measure>
    <time_frame>Change from before to after 6 months of treatment</time_frame>
    <description>Change in blood hematocrit value in percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic mountain sickness score</measure>
    <time_frame>Change from before to after 6 months of treatment</time_frame>
    <description>Chronic mountain sickness score (between 0 and 24, the higher the score the more severe the sickness) according to the available international scoring system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrovascular reactivity</measure>
    <time_frame>Change from before to after 6 months of treatment</time_frame>
    <description>Post-ischemia brachial artery dilation in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular reactivity</measure>
    <time_frame>Change from before to after 6 months of treatment</time_frame>
    <description>Hyperthermic microvascular dilation in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin mass</measure>
    <time_frame>Change from before to after 6 months of treatment</time_frame>
    <description>Total blood hemoglobin mass in mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary arterial pressure</measure>
    <time_frame>Change from before to after 6 months of treatment</time_frame>
    <description>Systolic and mean pulmonary arterial pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Change from before to after 6 months of treatment</time_frame>
    <description>24-hour systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep recording</measure>
    <time_frame>Change from before to after 6 months of treatment</time_frame>
    <description>Hypopnea-apnea index reported in number of events per hour</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypoxia, Altitude</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral acetazolamide (250 mg/day) intake for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral atorvastatin (40 mg/day) intake for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo pill (daily) intake for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>Daily acetazolamide pill intake</description>
    <arm_group_label>Acetazolamide</arm_group_label>
    <other_name>Diamox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Daily atorvastatin pill intake</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Daily placebo pill intake</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Age between 18 and 55 yrs

          -  Body mass index &lt;30kg/m²

          -  Born at &gt;3500 m, living for &gt;3 years at the local high altitude

          -  No diagnosis of cardiorespiratory, metabolic or neurological diseases

          -  No drug intake

          -  No smoker

          -  Chronic mountain sickness score ≥6

        Exclusion Criteria:

          -  Diagnosis of cardiorespiratory, metabolic and neurological diseases

          -  Systolic &gt; 130 mmHg and/or diastolic &gt; 85 mmHg blood pressure

          -  Drug intake

          -  Smoker

          -  Chronic mountain sickness score &lt;6
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Verges, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EXAL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuel Verges, PhD</last_name>
    <phone>0476766860</phone>
    <phone_ext>33</phone_ext>
    <email>sverges@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Association EXALT, UM Sport Pathologies, Hôpital Sud, Avenue Kimberley</name>
      <address>
        <city>Échirolles</city>
        <zip>38130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Verges, PhD</last_name>
      <phone>476766860</phone>
      <phone_ext>33</phone_ext>
      <email>sverges@chu-grenoble.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Altitude Sickness</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

